RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin
Sommer, W. H., Ceelen, F., Garcia-Albeniz, X., Paprottka, P. M., Auernhammer, C. J., Armbruster, M., Nikolaou, K., Haug, A. R., Reiser, M. F., & Theisen, D. (2013). Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. European Radiology, 23(11), 3094-3103. https://doi.org/10.1007/s00330-013-2925-8
To define predictive parameters of long progression-free survival (PFS) in patients undergoing radioembolisation of neuroendocrine liver metastases.
The following clinical and magnetic resonance imaging (MRI) parameters of 45 radioembolised patients (median age, 62 years; range, 43-75) were reviewed: age, gender, levels of chromogranin A and neuron-specific enolase (NSE), primary tumour site, Ki-67 proliferation index, hepatic tumour load, number of metastases, signal intensity characteristics, vascularisation, haemorrhagic and necrotic transformation and fluid-fluid levels. PFS was assessed according to RECIST 1.0. Statistical analysis included univariate Cox regression, Kaplan-Meier and multivariate regression.
Median PFS was 727 days (95 % CI, 378-964). In the univariate regression analysis, hypovascular metastases progressed earlier (111 vs 727 days; P <0.05). A Ki-67 a parts per thousand currency sign2 % was associated with a longer PFS than a Ki-67 of 3-20 % or > 20 % (911 vs 727 vs 210 days, respectively; P <0.05). Low NSE predicted longer PFS (911 vs 378 days; P <0.05). In the adjusted multivariate analysis, vascularisation (hypervascularisation vs. no hypervascularisation; P = 0.0009) and NSE level (low vs high; P = 0.0119) had the strongest influence on PFS.
Response to radioembolisation in patients with neuroendocrine liver metastases can be predicted by the metastatic vascularisation pattern, the NSE level and the Ki-67.
aEuro cent Radioembolisation is an effective treatment in hepatic metastases of neuroendocrine origin.
aEuro cent Pre-therapeutic vascularisation patterns of metastases on MRI can predict long progression-free survival.
aEuro cent Assessment of pre-therapeutic markers provides better therapy planning.